Reports Q2 revenue $221.9M, consensus $204.9M. “Our financial outperformance in the second quarter was bolstered by strong demand for our latest technology offerings, namely Tandem Mobi, which drove our expansion of the insulin pump market,” said John Sheridan,CEO. “The early enthusiasm for our expanding portfolio supports our strategy to offer our customers choice as we work to bring the benefits of our technology to more people living with diabetes worldwide.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- TNDM Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Stifel sees Tandem underperformance as ‘overreaction’ after Mobi survey
- Tandem, DexCom announce t:slim X2 insulin pump authorized by Health Canada
- Citi opens ‘positive catalyst watch’ on Tandem Diabetes into earnings
- Tandem Diabetes Care Welcomes New EVP and COO